A Novel Injury Site-Targeted Complement Inhibitor Which Protects against Lung Transplant Ischemia Reperfusion Injury

Self-reactive natural Abs initiate complement activation and injury following ischemia and reperfusion of certain tissues, but their role in post-ischemic lung injury is unknown. Here, we investigated the expression of two previously identified post-ischemic neoepitopes, namely a modified annexin IV epitope recognized by B4 IgM mAb, and an epitope consisting of a subset of phospholipids recognized by C2 IgM mAb, and additionally determined their role in lung transplant ischemia reperfusion injury (IRI).

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: C. Li, K. Patel, P. Allen, Z. TU, J. Kilkenny, C. Wallace, S. Nadig, S. Tomlinson, C. Atkinson Tags: 7 Source Type: research